Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	Hepatology 2012 (546 pages, free PDF) Hepatitis C 2012 (150 pages, free PDF)	Free Medical Books

Gynecology

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 48 articles: HTML format Text format

Single Articles

April 2012
1. MUNZONE E , Botteri E, Esposito A, Sciandivasci A, et al
   Outcome and clinical-biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases.
   Ann Oncol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
2. LINDEMANN K , Christensen RD, Vergote I, Stuart G, et al
   First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG.
   Ann Oncol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
3. ALTENA R , Gietema JA, van Veldhuisen DJ, Reyners AK, et al
   Pregnancy unbosoms the heart of breast cancer survivors.
   Ann Oncol. 2012.
   PubMed     Text format     Related articles   
   
   
   
   February 2012
4. BAUMANN KH , du Bois A, Meier W, Rau J, et al
   A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor mono
   Ann Oncol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
5. SEHOULI J , Runnebaum IB, Fotopoulou C, Blohmer U, et al
   A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study.
   Ann Oncol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   January 2012
6. BRUNDAGE M , Gropp M, Mefti F, Mann K, et al
   Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial.
   Ann Oncol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
7. BONDONG S , Kiefel H, Hielscher T, Zeimet AG, et al
   Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-kappaB activation.
   Ann Oncol. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   December 2011
8. BELL-MCGUINN K , Konner J, Tew W, Spriggs DR, et al
   New drugs for ovarian cancer.
   Ann Oncol. 2011;22 Suppl 8:viii77-viii82.
   PubMed     Text format     Related articles   
   
   
   
   
9. SESSA C
   Update on PARP1 inhibitors in ovarian cancer.
   Ann Oncol. 2011;22 Suppl 8:viii72-viii76.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
10. MARKMAN M
    The use of bevacizumab in the management of ovarian cancer: an argument for single-agent rather than combination therapy.
    Ann Oncol. 2011;22 Suppl 8:viii69-viii71.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
11. BURGER RA
    Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer.
    Ann Oncol. 2011;22 Suppl 8:viii65-viii68.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
12. URBAN N
    Designing early detection programs for ovarian cancer.
    Ann Oncol. 2011;22 Suppl 8:viii6-viii18.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
13. BAST RC JR
    Molecular approaches to personalizing management of ovarian cancer.
    Ann Oncol. 2011;22 Suppl 8:viii5-viii15.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. EISENHAUER EA
    Optimal assessment of response in ovarian cancer.
    Ann Oncol. 2011;22 Suppl 8:viii49-viii51.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
15. RUSTIN GJ
    Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed.
    Ann Oncol. 2011;22 Suppl 8:viii45-viii48.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
16. PIGNATA S , Cannella L, Leopardo D, Bruni GS, et al
    Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up.
    Ann Oncol. 2011;22 Suppl 8:viii40-viii44.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
17. VAN DER BURG ME , Boere IA, Berns PM
    Dose-dense therapy is of benefit in primary treatment of ovarian cancer: contra.
    Ann Oncol. 2011;22 Suppl 8:viii33-viii39.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. KATSUMATA N
    Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor.
    Ann Oncol. 2011;22 Suppl 8:viii29-viii32.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. KANG S , Park SY
    To predict or not to predict? The dilemma of predicting the risk of suboptimal cytoreduction in ovarian cancer.
    Ann Oncol. 2011;22 Suppl 8:viii23-viii28.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
20. HACKER NF
    Quality control in ovarian cancer surgery.
    Ann Oncol. 2011;22 Suppl 8:viii19-viii22.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
21. PUJADE-LAURAINE E , Alexandre J
    Update of randomized trials in recurrent disease.
    Ann Oncol. 2011;22 Suppl 8:viii61-viii64.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
22. BOOKMAN MA
    Update of randomized trials in first-line treatment.
    Ann Oncol. 2011;22 Suppl 8:viii52-viii60.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2011
23. TERADA K
    DNA ploidy in endometrial cancer: unfinished business?
    Ann Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
24. ROCHON J , du Bois A
    Clinical research in epithelial ovarian cancer and patients' outcome.
    Ann Oncol. 2011;22 Suppl 7:vii16-vii19.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
25. BRAGA S
    Why do our patients get chemotherapy until the end of life?
    Ann Oncol. 2011;22:2345-8.
    PubMed     Text format     Related articles   
    
    
    
    
26. NAPPA U , Lindqvist O, Rasmussen BH, Axelsson B, et al
    Palliative chemotherapy during the last month of life.
    Ann Oncol. 2011;22:2375-80.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2011
27. FAUVET R , Brzakowski M, Morice P, Resch B, et al
    Borderline ovarian tumors diagnosed during pregnancy exhibit a high incidence of aggressive features: results of a French multicenter study.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
28. EJLERTSEN B , Aldridge J, Nielsen KV, Regan MM, et al
    Prognostic and predictive role of ESR1 status for postmenopausal patients with endocrine-responsive early breast cancer in the Danish cohort of the BIG 1-98 trial.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. GLADIEFF L , Ferrero A, De Rauglaudre G, Brown C, et al
    Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2011
30. PRADHAN M , Abeler VM, Danielsen HE, Sandstad B, et al
    Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
31. COLOMBO N , Preti E, Landoni F, Carinelli S, et al
    Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2011;22 Suppl 6:vi35-9.
    PubMed     Text format     Related articles   
    
    
    
    August 2011
32. NAM JH , Park JY, Kim DY, Kim JH, et al
    Laparoscopic versus open radical hysterectomy in early-stage cervical cancer: long-term survival outcomes in a matched cohort study.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2011
33. SHIEH MP , Mehta RS
    Oligohydramnios associated with administration of weekly paclitaxel for triple-negative breast cancer during pregnancy.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
34. SEHOULI J , Alfaro V, Gonzalez-Martin A
    Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2011
35. LI Z , Yu CP, Zhong Y, Liu TJ, et al
    Sam68 expression and cytoplasmic localization is correlated with lymph node metastasis as well as prognosis in patients with early-stage cervical cancer.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
36. LORTHOLARY A , Largillier R, Weber B, Gladieff L, et al
    Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINE
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2011
37. TRAA MJ , De Vries J, Roukema JA, Den Oudsten BL, et al
    Sexual (dys)function and the quality of sexual life in patients with colorectal cancer: a systematic review.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
38. ARBYN M , Castellsague X, de Sanjose S, Bruni L, et al
    Worldwide burden of cervical cancer in 2008.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. LAVIE O , Narod S, Lejbkowicz F, Dishon S, et al
    Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population.
    Ann Oncol. 2011;22:964-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
40. ROSATO V , Bosetti C, Talamini R, Levi F, et al
    Metabolic syndrome and the risk of breast cancer in postmenopausal women.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
41. HADJI P , Aapro MS, Body JJ, Bundred NJ, et al
    Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
42. KURTZ JE , Kaminsky MC, Floquet A, Veillard AS, et al
    Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study.
    Ann Oncol. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2011
43. 
    Hereditary breast and ovarian cancer: risks and challenges. Proceedings of a meeting. September 10-12, 2009. Bari, Italy.
    Ann Oncol. 2011;22 Suppl 1:i5-68.
    PubMed     Text format     Related articles   
    
    
    
    
44. MUGGIA F , Safra T, Dubeau L
    BRCA genes: lessons learned from experimental and clinical cancer.
    Ann Oncol. 2011;22 Suppl 1:i7-10.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
45. MUGGIA F , Smaldone V, Paradiso A
    Conclusions: fruits of the convergence of laboratory, clinic and public.
    Ann Oncol. 2011;22 Suppl 1:i67-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
46. CALVERT H , Azzariti A
    The clinical development of inhibitors of poly(ADP-ribose) polymerase.
    Ann Oncol. 2011;22 Suppl 1:i53-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
47. RADICE P , De Summa S, Caleca L, Tommasi S, et al
    Unclassified variants in BRCA genes: guidelines for interpretation.
    Ann Oncol. 2011;22 Suppl 1:i18-23.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
48. MILNE RL , Antoniou AC
    Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers.
    Ann Oncol. 2011;22 Suppl 1:i11-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: